about
Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives.Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells.The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maiOncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.Targeting histone deacetylases: development of vorinostat for the treatment of cancer.Management of myeloma-associated renal dysfunction in the era of novel therapies.Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program.Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma.In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival.An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation
P2860
Q35514038-134D44DE-4128-4D32-A4EB-AB9D60376458Q35586471-6C594B6F-D479-41E2-8A63-323FB74BC39CQ36565628-7FDD4E8B-7D64-4B2B-B888-91FB1853A41EQ37381298-729973BD-6B9F-499B-AD5E-8A1CA8676533Q37961738-554A6B7A-0146-4EF6-94CE-BA12E01D74F7Q37978343-29DA60FA-220C-4F9A-864D-B570A7CFCE2FQ38025703-20B07584-B7C1-4BBE-B98F-E2D5FB23D126Q38095526-A3DE1CE2-3FAF-4992-B061-7C1D543D63BCQ38931762-810D68D8-4968-4876-80F3-F9975EF500E6Q41470772-F6E1AAC1-C58F-4DAE-8EA4-66B5262CBB4FQ42212863-F11D4057-4588-4BC9-A863-C8638C56B8E7Q57904533-3CAFE172-9B79-4BE1-87F4-8F4C52DC06FE
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel therapies in the treatment of multiple myeloma.
@en
Novel therapies in the treatment of multiple myeloma.
@nl
type
label
Novel therapies in the treatment of multiple myeloma.
@en
Novel therapies in the treatment of multiple myeloma.
@nl
prefLabel
Novel therapies in the treatment of multiple myeloma.
@en
Novel therapies in the treatment of multiple myeloma.
@nl
P2093
P356
P1476
Novel therapies in the treatment of multiple myeloma.
@en
P2093
Anuj Mahindra
Constantine S Mitsiades
Dharminder Chauhan
Irene M Ghobrial
Jacob P Laubach
Nicole A Carreau
Nikhil C Munshi
Noopur Raje
Robert L Schlossman
Teru Hideshima
P304
P356
10.6004/JNCCN.2009.0062
P577
2009-10-01T00:00:00Z